Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29151660 | 0.98 | HRH3 (0.48) | HRH3MAOBBCHEMEN1POLB | |
| Iodide SCHEMBL31530720 | 0.98 | HRH3 (0.48) | HRH3MAOBBCHEMEN1POLB | |
| SCHEMBL12513823 | 0.94 | BCHE (0.55) | HRH3MAOBBCHE | |
| SCHEMBL38663656 | 0.92 | BCHE (0.58) | HRH3BCHE | |
| SCHEMBL16596807 | 0.92 | BCHE (0.58) | HRH3BCHE | |
| SCHEMBL23505359 | 0.92 | HRH3 (0.44) | HRH3MAOBBCHEKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL30330336 | 0.92 | BCHE (0.54) | HRH3MAOBBCHE | |
| SCHEMBL2958521 | 0.92 | BCHE (0.58) | HRH3BCHE | |
| SCHEMBL18885442 | 0.92 | BCHE (0.58) | HRH3BCHE | |
| SCHEMBL20863150 | 0.92 | BCHE (0.58) | HRH3BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035821-A1 | LITHIUM RECOVERY FROM LITHIUM SALTS DISSOLVED IN IONIC LIQUIDS | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE (US) | 2026-02-05 | — | — | US | disclosed |
| US-12509359-B2 | Stoichiometric recovery of UF4 from UF6 dissolved in ionic liquids | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) | 2025-12-30 | — | — | US | disclosed |
| US-12467152-B2 | Lithium recovery from lithium salts dissolved in ionic liquids | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) | 2025-11-11 | — | — | US | disclosed |
| EP-3735411-B1 | 1,3,4,5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER`S DISEASE | AC IMMUNE SA (CH) | 2024-07-10 | — | — | EP | disclosed |
| US-20230107668-A1 | STOICHIOMETRIC RECOVERY OF UF4 FROM UF6 DISSOLVED IN IONIC LIQUIDS | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIV OF NEVAD (US) | 2023-04-06 | — | — | US | disclosed |
| US-20230102003-A1 | NON-AQUEOUS FREESTANDING ION CONDUCTIVE GEL FOR ELECTROLYTE OF LITHIUM SECONDARY BATTERY AND PREPARATION METHOD THEREOF | RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY (60%) (KR) | 2023-03-30 | — | — | US | disclosed |
| US-20230072690-A1 | LITHIUM RECOVERY FROM LITHIUM SALTS DISSOLVED IN IONIC LIQUIDS | The Board of Regents of the Nevada System of Higher Education on Behalf of the Univ of Nevada (US) | 2023-03-09 | — | — | US | disclosed |
| CN-115335543-A | Lithium recovery from lithium salts dissolved in ionic liquids | 内华达高等教育系统董事会代表拉斯维加斯内华达大学 | 2022-11-11 | — | — | CN | disclosed |
| CN-115335331-A | From UF dissolved in ionic liquids 6 Stoichiometric recovery of UF 4 | 内华达高等教育系统董事会代表拉斯维加斯内华达大学 | 2022-11-11 | — | — | CN | disclosed |
| EP-4081668-A1 | LITHIUM RECOVERY FROM LITHIUM SALTS DISSOLVED IN IONIC LIQUIDS | The Board of Regents of The Nevada System of Higher Education on behalf of the University of Nevada, Las Vegas (US) | 2022-11-02 | — | — | EP | disclosed |
| US-20110286080-A1 | ELECTROPHORETIC MEDIA, AND MATERIALS FOR USE THEREIN | E INK CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20100249111-A1 | MULTI-RING COMPOUNDS AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2010-09-30 | — | — | US | disclosed |
| CN-101784524-A | Ionic liquid | INVISTA TECH SARL | 2010-07-21 | — | — | CN | disclosed |
| EP-2162435-A1 | IONIC LIQUIDS AS ELECTROLYTES | Invista Technologies S.A.R.L. (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| WO-2008150842-A1 | IONIC LIQUIDS AS ELECTROLYTES | INVISTA TECHNOLOGIES S.A.R.L. (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080296531-A1 | IONIC LIQUIDS | INVISTA NORTH AMERICA S.A R.L. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20070238727-A1 | 5-Substituted 1-Phenyl-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones and Analogs as Anti-Virals | TIBOTEC BVBA (BE) | 2007-10-11 | — | — | US | disclosed |
| US-20070238727-A1 | 5-Substituted 1-Phenyl-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones and Analogs as Anti-Virals | TIBOTEC BVBA (BE) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035821-A1 | LITHIUM RECOVERY FROM LITHIUM SALTS DISSOLVED IN IONIC LIQUIDS | SLC9A2, SLC9A3, SLC6A6 | HRH3 1479/4885MAOB 4532/4885BCHE 4818/4885 |
| US-20090137576-A1 | Novel Piperidine Derivative | HRH4, HRH3, HRH1 | HRH3 2/4885MAOB 1314/4885BCHE 1131/4885 |
| US-20100249111-A1 | MULTI-RING COMPOUNDS AND USES THEREOF | TP53, BCOR, HPGDS | HRH3 3622/4885MAOB 1769/4885BCHE 2124/4885 |
| US-20070238727-A1 | 5-Substituted 1-Phenyl-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones and Analogs as Anti-Virals | NR5A2, NR5A1, NR4A1 | HRH3 122/4885MAOB 1697/4885BCHE 3223/4885 |
| US-12509359-B2 | Stoichiometric recovery of UF4 from UF6 dissolved in ionic liquids | UFL1, UFM1, PRPF4 | HRH3 2892/4885MAOB 4152/4885BCHE 4753/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | HRH3 788/4885MAOB 3514/4885BCHE 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.